
We need policies that make digital therapeutics accessible and acceptable to a broad patient audience. What barriers are there to reaching that goal?
Dr Lindhiem is an associate professor of psychiatry at the University of Pittsburgh.
We need policies that make digital therapeutics accessible and acceptable to a broad patient audience. What barriers are there to reaching that goal?